Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 60%
Buy 33%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc. is showing strong potential for growth based on increased revenue estimates and a revised outlook on its product pipeline, notably with Brensocatib expected to generate approximately $8.5 billion in peak sales by 2033. The company has also introduced revenue estimates for Treprostinil Palmitil Inhalation Powder (TPIP), further enhancing its market prospects in the treatment of interstitial lung disease and pulmonary arterial hypertension. Additionally, a decreased terminal decline rate in the discounted cash flow (DCF) calculation reflects heightened confidence in the long-term viability and profitability of Insmed's innovative therapies.

Bears say

Insmed Inc faces significant uncertainty due to potential delays in enrolling and completing clinical studies for its key products, Arikayce, Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP), which could negatively impact the company's probability of success and overall valuation. Additionally, projections indicate that TPIP may not enter the idiopathic pulmonary fibrosis (IPF) market before 2034, contingent on the approval of a competing product, Tyvaso, in 2027, due to orphan drug exclusivity considerations. These factors contribute to a cautious outlook on Insmed's financial stability and growth potential in the near to medium term.

Insmed (INSM) has been analyzed by 15 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 33% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 15 analysts, Insmed (INSM) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $180.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $180.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.